MASSDEVICE ON CALL — Dr. George Bakris, the co-principal investigator for Medtronic‘s (NYSE:MDT) failed Symplicty-3 renal denervation trial, believes further clinical work should be tabled until a few key questions about the therapy are answered.
Rox Medical said it closed enrollment in a 100-patient clinical trial of its Rox Coupler device, designed to treat hypertension by connecting the femoral artery and the femoral vein.
CEO Rodney Brenneman told MassDevice.com that Rox Medical, a Stanford spinout established in 2004 to pursue several indications including chronic obstructive lung disease and heart failure, noticed a dramatic effect on high blood pressure in COPD patients implanted with the device.
MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.
MASSDEVICE ON CALL — Medtech titan Medtronic (NYSE:MDT) took a risk when it bet nearly $1 billion on renal denervation pioneer Ardian years before its flagship device was slated to hit the U.S. market, and the recent foofaraw over the company’s missed clinical trial may have a cooling effect on other device companies, analysts warned.